Regulatory Affairs advanced
Peptide Drug 505(b)(2) Development
Development pathway for modified peptide drug products using the FDA 505(b)(2) regulatory pathway. This peptide or oligopeptide is studied for its biological...
By Encyclopeptide Editorial | 1 min read
505b2 modified-drug regulatory reference-drug new-formulation
Overview
The 505(b)(2) pathway allows development of modified peptide drug products by referencing existing safety and efficacy data.
505(b)(2) vs ANDA
| Feature | 505(b)(2) | ANDA |
|---|---|---|
| Modification | Yes (new dosage form, | No (same as reference) |
| new route, new strength) | ||
| Studies needed | Limited new studies | Bioequivalence only |
| Exclusivity | 3 years | None |
Qualifying Modifications
- New dosage form
- New route of administration
- New strength
- New combination
- Limited changes requiring new data
Development Considerations
- Selection of reference drug
- Justification for modification
- Clinical study requirements
- Marketing exclusivity
Test Your Knowledge
Reinforce what you learned about Peptide Drug 505(b)(2) Development with interactive quizzes on Wikipept.
Take a Quiz on Wikipept